



Newron to Present at the 17th Annual BIO CEO & Investor Conference and the Leerink Global Healthcare Conference

February 5, 2015 – Milan, Italy – [Newron Pharmaceuticals S.p.A.](#) (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Stefan Weber, CEO, will provide a company update at the 17th Annual BIO CEO & Investor Conference in New York City. The presentation is on Feb. 9, 2015, at 4 p.m. in the Conrad room at the Waldorf Astoria hotel.

Newron also will present at the Leerink Global Healthcare Conference on Feb. 11, 2015, at 1:25 p.m. at the Waldorf Astoria hotel.

The [BIO CEO & Investor Conference](#) is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year, the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions and educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings and networking opportunities.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy.

Marketing authorization in the EU for Xadago™ (safinamide) is expected in 2015. The Committee for Medicinal Products for Human Use (CHMP) recommended to approve safinamide in the EU on Dec. 19, 2014 following the submission of the Marketing Authorization Application (MAA) for safinamide to the European Medicines Agency (EMA) for the treatment of Parkinson's disease. The New Drug Application NDA to the U.S. FDA has been re-submitted by Newron on Dec. 26, 2014. In March 2014, Zambon Group, a partner of Newron, submitted a MAA to Swissmedic. Zambon has the rights to commercialize safinamide globally, excluding Japan and other key Asian territories where Meiji Seika has the rights to develop and commercialize the compound.

Newron's additional projects are based on highly promising treatments for rare disease patients and are at various stages of clinical development, including sarizotan for patients with Rett syndrome, sNN0031 for patients with Parkinson's disease, non-responsive to oral drug treatments, sNN0029 for patients with ALS and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

For more information, please visit: www.newron.com

###

For more information, contact:

Corporate:

Stefan Weber, CEO

+39 02 6103 46 26

pr@newron.com

U.S. Investors:

LaVoieHealthScience

Donna LaVoie

617-374-8800, Ext. 108

dlavoie@lavoiehealthscience.com

U.S. Media:

LaVoieHealthScience

Kristina Coppola

617-374-8800, Ext. 105

kcoppola@lavoiehealthscience.com